Table 1.
Characteristics of the included studies
| Study | Sample size (C/E) |
Age (C/E; y) |
Man (%) | Course of disease (C/E; d) |
Treatment (C/E) |
Therapeutic time(week) |
|---|---|---|---|---|---|---|
| Wang Bo,2013 | 35 | 10.3 ± 3.9 | 36(51.4) | NR | azithromycin10mg/Kg·d; minocycline4mg/Kg·d | 1 |
| 35 | 9.4 ± 4.5 | azithromycin10mg/Kg/d | ||||
| Yi Qiaoling,2013 | 28 | 12.3 ± 3.8 | 29(51.8) | NR | erythromycin、azithromycin30-50 mg/Kg·d; minocycline4mg/Kg·d | 1 |
| 28 | 12.6 ± 3.9 | erythromycin、azithromycin30-50 mg/Kg·d | ||||
| Zheng Qingkai,2018 | 40 | 11.1(8–14) | 48(60.0) | NR | azithromycin10mg/Kg·d; minocycline4mg/Kg·d | 1 |
| 40 | 10.7(7–13) | azithromycin10mg/Kg·d | ||||
| Liang Zou,2016 | 23 | 11.4 ± 2.7 | 25(54.3) | NR | azithromycin2mg/mL·d; minocycline4mg/Kg·d | 1 |
| 23 | 12.5 ± 2.6 | azithromycin2mg/mL·d | ||||
| Chen Ying,2012 | 20 | 11.6 ± 2.1 | 19(47.5) | NR | erythromycin、azithromycin; minocycline4mg/Kg·d | 1 |
| 20 | erythromycin、azithromycin | |||||
| Wang Yongxia,2013 | 19 | 10.47 ± 1.98 | 20(54.1) | NR | azithromycin10mg/Kg·d; minocycline4mg/Kg·d | 4 |
| 18 | 10.41 ± 1.98 | azithromycin10mg/Kg/d | ||||
| Rao Fuguang,2016 | 44 | 8.9 ± 1.7 | 51(58.0) | 2.4 ± 0.9 | azithromycin10mg/Kg·d; minocycline4mg/Kg·d | 4 |
| 44 | 8.6 ± 2.2 | 2.2 ± 0.7 | azithromycin10mg/Kg/d | |||
| Huang Wei,2018 | 40 | 6.51 ± 1.50 | 49(61.3) | 12.30 ± 1.25 | azithromycin10mg/Kg·d; minocycline4mg/Kg·d | 4 |
| 40 | 7.62 ± 1.41 | 13.12 ± 1.06 | azithromycin10mg/Kg/d | |||
| Sun Xiangyang,2016 | 120 | 9.6 ± 1.9 | 58(48.3) | 5.8 ± 1.2 | azithromycin10mg/Kg/d, minocycline 50 mg, twice a day | Discontinue 2 days after fever subsides |
| 120 | 9.8 ± 2.0 | 56(46.7) | 6.0 ± 1.3 | azithromycin10mg/Kg/d | ||
| Xu Xiaohong,2017 | 60 | 9.2 ± 2.1 | 32(50.3) | NR | azithromycin10mg/Kg/d, minocycline 50 mg, twice a day | Discontinue 2 days after fever subsides |
| 60 | 8.9 ± 2.4 | 33(55.0) | azithromycin10mg/Kg/d |
C Control group, E Experimental group, NR Not reported